NewLink Genetics (NLNK) Strengthens Patent on Cancer Therapy D-1MT
Tweet Send to a Friend
Up)
NewLink Genetics (Nasdaq: NLNK) received a 'notice of allowance' from USPTO regarding its patent on cancer therapy D-1MT, allowing it broader rights to protection.
"These patents will strengthen our D-1MT franchise in the United States," commented Dr. Charles Link, NewLink's Chairman and CEO, "and should facilitate our ongoing discussions with potential development and marketing partners for this product candidate."
IDO pathway inhibitors, including D-1MT, represent a potential breakthrough approach to cancer therapy using small-molecule, anti-toleragenic product candidates intended to counteract a key mechanism by which tumors evade immune-mediated destruction.
Get Alerted Instantly When News Breaks on NLNK and Other Stocks with EasyStockAlerts.com
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"These patents will strengthen our D-1MT franchise in the United States," commented Dr. Charles Link, NewLink's Chairman and CEO, "and should facilitate our ongoing discussions with potential development and marketing partners for this product candidate."
IDO pathway inhibitors, including D-1MT, represent a potential breakthrough approach to cancer therapy using small-molecule, anti-toleragenic product candidates intended to counteract a key mechanism by which tumors evade immune-mediated destruction.
Get Alerted Instantly When News Breaks on NLNK and Other Stocks with EasyStockAlerts.com
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Jefferies Starts NewLink Genetics (NLNK) at Buy
- Zion Oil (ZN) Plans In-Well Testing of Elijah #3
- Himax (HIMX) Receives Letter from U.S. Counsel Over Secondary ADS Offering
Create E-mail Alert Related Categories
Corporate News
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
